bioAffinity Technologies (BIAF) Competitors $0.33 +0.04 (+12.67%) Closing price 04:00 PM EasternExtended Trading$0.31 -0.02 (-5.15%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIAF vs. RSLS, OFAL, XBP, GLE, SWAG, WAI, DTST, SCOR, FPAY, and SGRPShould you be buying bioAffinity Technologies stock or one of its competitors? The main competitors of bioAffinity Technologies include ReShape Lifesciences (RSLS), OFA Group (OFAL), XBP Europe (XBP), Global Engine Group (GLE), Stran & Company, Inc. (SWAG), Top KingWin (WAI), Data Storage (DTST), comScore (SCOR), FlexShopper (FPAY), and SPAR Group (SGRP). bioAffinity Technologies vs. Its Competitors ReShape Lifesciences OFA Group XBP Europe Global Engine Group Stran & Company, Inc. Top KingWin Data Storage comScore FlexShopper SPAR Group ReShape Lifesciences (NASDAQ:RSLS) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Do analysts recommend RSLS or BIAF? bioAffinity Technologies has a consensus price target of $6.00, indicating a potential upside of 1,718.18%. Given bioAffinity Technologies' higher possible upside, analysts plainly believe bioAffinity Technologies is more favorable than ReShape Lifesciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ReShape Lifesciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00bioAffinity Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is RSLS or BIAF more profitable? ReShape Lifesciences has a net margin of -48.26% compared to bioAffinity Technologies' net margin of -110.53%. ReShape Lifesciences' return on equity of -251.90% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets ReShape Lifesciences-48.26% -251.90% -59.49% bioAffinity Technologies -110.53%-367.64%-154.15% Does the media refer more to RSLS or BIAF? In the previous week, bioAffinity Technologies had 1 more articles in the media than ReShape Lifesciences. MarketBeat recorded 2 mentions for bioAffinity Technologies and 1 mentions for ReShape Lifesciences. ReShape Lifesciences' average media sentiment score of 1.87 beat bioAffinity Technologies' score of 0.14 indicating that ReShape Lifesciences is being referred to more favorably in the media. Company Overall Sentiment ReShape Lifesciences Very Positive bioAffinity Technologies Neutral Which has better earnings and valuation, RSLS or BIAF? ReShape Lifesciences has higher earnings, but lower revenue than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReShape Lifesciences$8.01M0.84-$7.13M-$193.23-0.01bioAffinity Technologies$9.36M1.00-$9.04M-$0.72-0.46 Which has more risk & volatility, RSLS or BIAF? ReShape Lifesciences has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Do institutionals & insiders have more ownership in RSLS or BIAF? 22.1% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 0.0% of ReShape Lifesciences shares are owned by insiders. Comparatively, 16.9% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryReShape Lifesciences and bioAffinity Technologies tied by winning 7 of the 14 factors compared between the two stocks. Get bioAffinity Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for BIAF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIAF vs. The Competition Export to ExcelMetricbioAffinity TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.34M$2.91B$5.52B$9.32BDividend YieldN/A2.46%4.25%4.05%P/E Ratio-0.4620.3628.1519.68Price / Sales1.00302.56437.63100.28Price / CashN/A42.3835.5357.53Price / Book1.947.768.235.67Net Income-$9.04M-$55.11M$3.23B$257.51M7 Day Performance-2.94%0.95%-0.01%0.52%1 Month Performance25.86%8.44%5.61%8.84%1 Year Performance-86.42%-2.38%26.52%14.18% bioAffinity Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIAFbioAffinity Technologies1.3675 of 5 stars$0.33+12.7%$6.00+1,718.2%-88.4%$8.34M$9.36M-0.4610News CoverageGap UpRSLSReShape Lifesciences0.6099 of 5 stars$2.38+0.4%N/A-99.2%$5.65M$8.01M-0.0150OFALOFA GroupN/A$1.97-4.4%N/AN/A$27.52M$386.36K0.006News CoverageGap UpXBPXBP EuropeN/A$0.89-1.2%N/A-39.8%$27.36M$142.77M0.001,450Gap DownGLEGlobal Engine GroupN/A$1.49-1.3%N/AN/A$27.18M$6.33M0.003SWAGStran & Company, Inc.2.4375 of 5 stars$1.40-2.1%N/A+30.5%$26.61M$92.52M-6.3670Gap DownWAITop KingWinN/A$0.72-80.2%N/AN/A$26.57M$3.75M0.00N/AGap DownHigh Trading VolumeDTSTData Storage0.8433 of 5 stars$3.53-1.4%N/A-47.1%$25.56M$25.37M176.5960News CoveragePositive NewsAnalyst ForecastGap UpSCORcomScore2.5812 of 5 stars$5.06+0.8%$10.75+112.5%-61.0%$24.84M$356.05M-0.321,200Gap DownFPAYFlexShopper3.5753 of 5 stars$0.99-13.9%$3.25+228.3%-13.5%$24.68M$139.80M-4.30140SGRPSPAR Group3.6486 of 5 stars$0.91-3.0%N/A-56.3%$22.06M$196.81M1.793,425 Related Companies and Tools Related Companies ReShape Lifesciences Competitors OFA Group Competitors XBP Europe Competitors Global Engine Group Competitors Stran & Company, Inc. Competitors Top KingWin Competitors Data Storage Competitors comScore Competitors FlexShopper Competitors SPAR Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIAF) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bioAffinity Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIAF Stock Alerts